Compare Adaptive Biotechnologies Corp (ADPT) vs Honest Company Inc (HNST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Honest Company Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.87 (market cap $3.33B), while Honest Company Inc trades at $3.89 (market cap $433.71M). The key difference: Adaptive Biotechnologies Corp is far larger — about 7.7× Honest Company Inc's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Honest Company Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | HNST | |
|---|---|---|
Market Cap | $3.33B | $433.71M |
Sector | Health | Consumer Staples |
52-Week High | $22.37 | $4.95 |
52-Week Low | $10.24 | $2.10 |
Enterprise Value | $3.19B | $355.11M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
HNST trades at $3.94, up 1.03% with a bullish technical signal from moving averages. The company reported Q1 2026 EPS of $0.01, meeting expectations, but maintains negative net income margins. Revenue declined to $371.32M in 2025 from $378M in 2024, though gross margins improved to 33.89%. Operating cash flow strengthened to $15.12M, supporting liquidity. Analyst sentiment is mixed with 30% buy ratings amid ongoing profitability challenges.
The outlook remains cautious due to persistent net losses and revenue volatility. Investment appeal hinges on margin expansion and sustained cash flow generation. Key risks include competitive pressures in personal care and execution on growth initiatives. The stock's elevated P/E of 48.83 suggests high expectations for future earnings recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Honest Company Inc
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →
